Search results
Results From The WOW.Com Content Network
The choice between the drugs is to a large degree determined by the characteristics of the patient being prescribed for, the drugs' side effects, and cost. Most drugs have other uses; sometimes the presence of other symptoms can warrant the use of one particular antihypertensive. Examples include: Age can affect the choice of medications.
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Tiếng Việt; 中文; Edit links ... Combination antihypertensive drugs (26 P) D. Diuretics (6 C, 51 P) Σ. Antihypertensive agent stubs (93 P) Pages in category ...
Several classes of medications, collectively referred to as antihypertensive medications, are available for treating hypertension. Use should take into account the person's cardiovascular risk (including risk of myocardial infarction and stroke), as well as blood pressure readings, in order to gain a more accurate picture of the person's risks.
Antihypertensive drug (high blood pressure) Antihypotensive agent (low blood pressure) This page was last edited on 20 November 2023, at 16:14 (UTC). Text is ...
The angiotensin receptor blockers (ARBs), also called angiotensin (AT1) receptor antagonists or sartans, are a group of antihypertensive drugs that act by blocking the effects of the hormone angiotensin II (Ang II) in the body, thereby lowering blood pressure.
This page was last edited on 5 November 2023, at 02:16 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Aprocitentan was approved for medical use in the United States in March 2024. [1]In April 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Jeraygo, intended for the treatment of resistant hypertension in adults.